These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 11851731)

  • 21. [Different botulinum toxins and their specifications].
    Beylot C
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S77-85. PubMed ID: 19576490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanism of therapy effects by botulinum neurotoxin].
    Alajbegović A; Alajbegović S; Resić H
    Med Arh; 2008; 62(1):53-5. PubMed ID: 18543757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
    Dolly JO; Wang J; Zurawski TH; Meng J
    FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches.
    Coffield JA; Bakry N; Zhang RD; Carlson J; Gomella LG; Simpson LL
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1489-98. PubMed ID: 9067339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology and clinical applications of botulinum toxins A and B.
    Thakker MM; Rubin PA
    Int Ophthalmol Clin; 2004; 44(3):147-63. PubMed ID: 15211183
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacology and immunology of botulinum neurotoxins.
    Aoki KR
    Int Ophthalmol Clin; 2005; 45(3):25-37. PubMed ID: 15970764
    [No Abstract]   [Full Text] [Related]  

  • 27. [Mode of action and effects of botulinum neurotoxin A].
    Périé S; Lacau St-Guily J
    Ann Otolaryngol Chir Cervicofac; 1996; 113(2):73-8. PubMed ID: 8999747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanisms of action of botulinum toxins and neurotoxins].
    Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons among botulinum toxins: an evidence-based review.
    Klein AW; Carruthers A; Fagien S; Lowe NJ
    Plast Reconstr Surg; 2008 Jun; 121(6):413e-422e. PubMed ID: 18520868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.
    Ferrari A; Manca M; Tugnoli V; Alberto L
    Funct Neurol; 2018; 33(1):7-18. PubMed ID: 29633692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum neurotoxin types B and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the three-dimensional structure of type A neurotoxin.
    Prabakaran S; Tepp W; DasGupta BR
    Toxicon; 2001 Oct; 39(10):1515-31. PubMed ID: 11478959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botox: the poison that heals.
    Khanna S; Jain S
    Int Dent J; 2006 Dec; 56(6):356-8. PubMed ID: 17243469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The application of botulinum toxin in the prostate.
    Chuang YC; Chancellor MB
    J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for antinociceptive activity of botulinum toxin type A in pain management.
    Aoki KR
    Headache; 2003; 43 Suppl 1():S9-15. PubMed ID: 12887389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
    Figgitt DP; Noble S
    Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin type B (Myobloc).
    Baumann L; Black L
    Dermatol Surg; 2003 May; 29(5):496-500; discussion 500. PubMed ID: 12752517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternatives to the use of animals for bacterial toxins and antitoxins.
    Sesardic D
    Dev Biol Stand; 1999; 100():75-82. PubMed ID: 10616178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin in clinical practice.
    Jankovic J
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):951-7. PubMed ID: 15201348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.
    Eleopra R; Tugnoli V; Rossetto O; Montecucco C; De Grandis D
    Neurosci Lett; 1997 Mar; 224(2):91-4. PubMed ID: 9086464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue.
    Kalandakanond S; Coffield JA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):749-55. PubMed ID: 11181902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.